| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2004 | CA2494916A1 Medicinal composition for lowering blood lipid level |
| 02/19/2004 | CA2494911A1 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | CA2494908A1 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494785A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | CA2494776A1 Crystal forms of quinoxaline-2-carboxylic acid ¬4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl|-amide |
| 02/19/2004 | CA2494742A1 Tiacumicin production |
| 02/19/2004 | CA2494716A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 02/19/2004 | CA2494699A1 Palatable controlled-release formulation for companion animals |
| 02/19/2004 | CA2494677A1 Derivatives of monosaccharides for drug discovery |
| 02/19/2004 | CA2494660A1 Use of carboxamides for the treatment of tinnitus |
| 02/19/2004 | CA2494623A1 Polyisoprenylbenzophenone derivatives, method for production and use thereof |
| 02/19/2004 | CA2494585A1 Methods for the treatment of dementia based on apo e genotype |
| 02/19/2004 | CA2494334A1 Method and compositions for inducing production of fibrous organic tissue |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494270A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | CA2494269A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
| 02/19/2004 | CA2494259A1 Epothilone derivatives |
| 02/19/2004 | CA2494173A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | CA2494156A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 02/19/2004 | CA2494108A1 Amyloid immunization and cox-2 inhibitors for the treatment of alzheimer's disease |
| 02/19/2004 | CA2494065A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine |
| 02/19/2004 | CA2494028A1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493908A1 Thiophene compounds |
| 02/19/2004 | CA2493725A1 Antitumoral analogs of lamellarins |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493625A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | CA2493575A1 Tyrosine kinase inhibitors |
| 02/19/2004 | CA2493491A1 Process for selective production of aryl 5-thio-.beta.-d-aldohexopyranosides |
| 02/19/2004 | CA2493146A1 Antimicrobial aza-bicyclic derivates, their compositions and uses |
| 02/19/2004 | CA2493143A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | CA2493008A1 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | CA2492837A1 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
| 02/19/2004 | CA2491287A1 N-aryl-2-oxazolidinones and their derivatives |
| 02/19/2004 | CA2478889A1 Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| 02/19/2004 | CA2475305A1 Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| 02/18/2004 | EP1389637A1 Novel forms of interfering RNA molecules |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389616A1 Novel benzylpiperidine compound |
| 02/18/2004 | EP1389611A1 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/18/2004 | EP1389480A1 Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| 02/18/2004 | EP1389468A1 Compositions for promoting healing of bone fracture |
| 02/18/2004 | EP1389467A1 Therapeutic compositions for repairing chondropathy |
| 02/18/2004 | EP1389466A1 Immunopotentiators |
| 02/18/2004 | EP1389463A1 Medicine for inhibiting drug elimination pump |
| 02/18/2004 | EP1389462A1 Amorphous cefditoren pivoxil composition and process for producing the same |
| 02/18/2004 | EP1389460A1 Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
| 02/18/2004 | EP1389306A2 Method for detecting progredient chronic dementia, and corresponding peptides and detection reagents |
| 02/18/2004 | EP1389237A2 Novel fibroblast growth factors |
| 02/18/2004 | EP1389236A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 02/18/2004 | EP1389213A1 3,7-diazabicyclo 3.3.1] formulations as antiarhythmic compounds |
| 02/18/2004 | EP1389212A1 3,7-diazabicyclo 3.3.1] formulations as anti-arrythmic compounds |
| 02/18/2004 | EP1389211A1 3,7-diazybicyclo 3.3.1] formulations as antiarrhytmic compounds |
| 02/18/2004 | EP1389210A1 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same |
| 02/18/2004 | EP1389209A1 Folate mimetics and folate-receptor binding conjugates thereof |
| 02/18/2004 | EP1389208A1 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists) |
| 02/18/2004 | EP1389207A1 Polymorphic and other crystalline forms of cis-ftc |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389204A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 02/18/2004 | EP1389203A2 Analogs of thalidomide as potential angiogenesis inhibitors |
| 02/18/2004 | EP1389202A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 02/18/2004 | EP1389201A1 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/18/2004 | EP1389199A1 Chiral compounds |
| 02/18/2004 | EP1389197A1 Two-step conversion of protected taxane ester to paclitaxel |
| 02/18/2004 | EP1389196A1 Three-step conversion of protected taxane ester to paclitaxel |
| 02/18/2004 | EP1389194A2 Inhibitors of bace |
| 02/18/2004 | EP1389189A2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 02/18/2004 | EP1389183A1 Sulfonamide derivatives |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389180A1 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use |
| 02/18/2004 | EP1389133A1 Methods for inactivating viruses |
| 02/18/2004 | EP1389131A2 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389129A1 Methods of treating respiratory conditions |
| 02/18/2004 | EP1389127A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase |
| 02/18/2004 | EP1389122A2 Prevention of epithelial cancer |
| 02/18/2004 | EP1389121A1 Method and compositions for treating mammalian nerve tissue injuries |
| 02/18/2004 | EP1389120A2 Identifying parasitic fungi of the organism, and treatment thereof |
| 02/18/2004 | EP1389119A1 A pharmaceutical composition comprising lysophosphatidic acid |
| 02/18/2004 | EP1389118A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle |
| 02/18/2004 | EP1389117A1 Means and method for hormonal contraception |
| 02/18/2004 | EP1389116A1 Cathartic composition |
| 02/18/2004 | EP1389115A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |
| 02/18/2004 | EP1389114A2 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 02/18/2004 | EP1389113A1 Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389111A1 COMPOSITION FOR INHIBITING HIV ACTIVITY EXTRACTED FROM i PAECILOMYCES SP. /i (TOCHU-KASO) J300 |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389109A1 Gastric acid secretion inhibiting composition |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1389107A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| 02/18/2004 | EP1389106A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 02/18/2004 | EP1389105A1 Method of treatment |
| 02/18/2004 | EP1389104A2 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists |
| 02/18/2004 | EP1389103A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 02/18/2004 | EP1389102A1 Use of rare earth compounds for the prevention of kidney stone disease |